Alaunos Therapeutics, Inc. Share-based Payment Arrangement, Expense, after Tax
Alaunos Therapeutics, Inc. (TCRT) reported Share-based Payment Arrangement, Expense, after Tax of $6.83 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2021-03-01
- Alaunos Therapeutics, Inc. share-based payment arrangement, expense, after tax for fiscal 2020 was $6.83M, a 7.70% increase from fiscal 2019.
- Alaunos Therapeutics, Inc. share-based payment arrangement, expense, after tax for fiscal 2019 was $6.34M, a 15.83% decline from fiscal 2018.
- Alaunos Therapeutics, Inc. share-based payment arrangement, expense, after tax for fiscal 2018 was $7.53M, a 10.88% decline from fiscal 2017.
- Alaunos Therapeutics, Inc. share-based payment arrangement, expense, after tax for fiscal 2017 was $8.45M, a 0.02% increase from fiscal 2016.
| Period end | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|
| 2020-12-31 | $6.83M 10-K · filed 2021-03-01 |
| 2019-12-31 | $6.34M 10-K · filed 2021-03-01 |
| 2018-12-31 | $7.53M 10-K · filed 2021-03-01 |
| 2017-12-31 | $8.45M 10-K · filed 2020-03-02 |
| 2016-12-31 | $8.45M 10-K · filed 2019-03-05 |
| 2015-12-31 | $8.00M 10-K · filed 2018-03-01 |
| 2014-12-31 | $4.74M 10-K · filed 2017-02-16 |
| 2013-12-31 | $3.51M 10-K · filed 2016-02-24 |
| 2012-12-31 | $4.88M 10-K · filed 2015-02-26 |
| 2011-12-31 | $2.76M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |